Related Experiment Videos
Canavan disease: diagnosis and molecular analysis.
1Department of Pediatric and Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston 77555-0359, USA.
Genetic Testing
|January 1, 1997
Summary
Canavan disease, a genetic brain disorder, is diagnosed by elevated N-acetylaspartic acid levels. Carrier testing for Ashkenazi Jews is now possible due to identified gene mutations and high carrier frequency.
Area of Science:
- Genetics
- Biochemistry
- Neurology
Background:
- Canavan disease is an autosomal recessive neurological disorder.
- It is characterized by spongy degeneration of the brain.
- Prevalence is increased among the Ashkenazi Jewish population.
Purpose of the Study:
- To identify the genetic basis of Canavan disease.
- To establish carrier testing protocols for the Ashkenazi Jewish population.
Main Methods:
- Biochemical analysis for N-acetylaspartic acid levels.
- Gene cloning and mutation analysis of the aspartoacylase gene.
- Molecular analysis of healthy individuals for specific mutations.
Main Results:
- Increased N-acetylaspartic acid levels confirmed as a biochemical marker.
- Two specific mutations in the aspartoacylase gene identified in 98% of Ashkenazi Jewish patients.
- High carrier frequency for Canavan disease detected in the healthy Jewish population.
Conclusions:
- Accurate diagnosis of Canavan disease is achievable through biochemical and molecular markers.
- Carrier testing for Canavan disease is feasible and recommended for the Jewish population.
- Understanding carrier frequency aids in genetic counseling and disease management.